Retatrutide Tracker App
Track the Triple Agonist Revolution
Prepare to track Retatrutide - Eli Lilly's breakthrough triple GIP/GLP-1/glucagon receptor agonist. Phase 2 trials showed up to 24% weight loss - the most ever seen with any medication. Be ready when it launches.
What is Retatrutide?
Retatrutide is Eli Lilly's next-generation obesity medication currently in Phase 3 trials. Unlike tirzepatide (Mounjaro/Zepbound) which targets two receptors, retatrutide is a triple agonist that activates GIP, GLP-1, AND glucagon receptors for unprecedented weight loss.
In Phase 2 trials, participants lost up to 24.2% of their body weight in 48 weeks - surpassing even tirzepatide's impressive results. The addition of glucagon receptor activation helps increase energy expenditure and fat burning.
Retatrutide is expected to receive FDA approval in 2025-2026. Shotlee will be ready to support full tracking from day one, including custom dosing and side effect monitoring.
FAQ
When will Retatrutide be available?
Retatrutide is currently in Phase 3 trials. FDA approval is expected in 2025-2026. Shotlee will support it immediately upon launch.
How is Retatrutide different from Mounjaro?
While Mounjaro activates 2 receptors (GIP + GLP-1), Retatrutide activates 3 (GIP + GLP-1 + glucagon). This triple action leads to greater weight loss and metabolic benefits.